MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
NRC stock logo

NRC

National Research Corporation

$21.04
1.29
 (6.53%)
Exchange:  NASDAQ
Market Cap:  474.186M
Shares Outstanding:  6M
Delayed data
Calculate NRC Intrinsic Value
5-year outlook →
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Healthcare Information Services
   
CEO:  Trent Green
Full Time Employees:  368
Address: 
1245 Q Street
Lincoln
NE
68508
US
Website:  https://nrchealth.com
National Research Corporation (NRC) empowers healthcare organizations across the United States and Canada with data-driven analytics and actionable insights to enhance both patient and employee experiences. Through a comprehensive suite of subscription-based solutions, NRC supplies crucial information and analysis, addressing vital aspects such as the overall patient journey, service recovery initiatives, effective transitions of care, health risk assessments, fostering employee engagement, and enhancing reputation management and brand loyalty. Beyond these, NRC provides market intelligence to help organizations understand brand awareness, public perception, and competitive positioning. They offer advanced segmentation tools to analyze community needs, wants, and behaviors in real-time. Specialized health risk assessment tools are available to help clients pinpoint and support high-risk populations, fostering preventative care strategies and wellness initiatives. Similarly, transition management solutions assist in identifying and managing at-risk patients during care changes, aiming to reduce readmissions and ensure smooth, satisfactory transitions. NRC also offers transparency tools, empowering healthcare providers to present clear organizational information to consumers, thereby supporting informed decision-making. Furthermore, governance solutions are tailored for the leadership of non-profit hospitals and health systems, including boards of directors, executives, and physician leaders. Their clientele includes integrated health systems, post-acute care providers, and healthcare payer organizations. Established in 1981, National Research Corporation maintains its headquarters in Lincoln, Nebraska.

Click to read more…

Revenue Segmentation

MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2026/02/03 — Q4 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue148,580143,060137,390
Gross Profit92,56586,12777,395
EBITDA45,98541,30730,230
Operating Income40,04535,19422,590
Net Income30,97124,78311,600

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets122,437132,539134,878
Total Liabilities73,482101,255120,888
Total Stockholders Equity48,95531,28413,990
Total Debt38,95662,68479,035
Cash and Cash Equivalents6,6534,2334,139

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow38,11334,62526,450
Capital Expenditure-15,779-15,448-10,706
Free Cash Flow22,33419,17715,744
Net Income30,97124,78311,600
Net Change in Cash-18,373-2,420-94

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2028Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)129,300Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)129,300Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)129,300Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)39,475.539Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)39,475.539Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)39,475.539Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)25,979.361Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)25,979.361Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)25,979.361Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)40,635.719Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)40,635.719Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)40,635.719Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)1.160Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)1.160Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)1.160Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
143.06M  ?P/S
 (TTM)
: 
3.11
?Net Income
 (TTM)
: 
24.781M  ?P/E
 (TTM)
: 
46.18
?Enterprise Value
 (TTM)
: 
506.837M  ?EV/FCF
 (TTM)
: 
29.08
?Dividend Yield
 (TTM)
: 
0.03  ?Payout Ratio
 (TTM)
: 
1.31
?ROE
 (TTM)
: 
0.57  ?ROIC
 (TTM)
: 
0.12
?Net Debt
 (TTM)
: 
59.616M  ?Debt/Equity
 (TTM)
: 
5.78
?P/B
 (TTM)
: 
30.92  ?Current Ratio
 (TTM)
: 
0.52

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
23.91Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates NRC intrinsic value between $11.88 – $16.86 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.

[intrinsic_calculator]

Common questions about NRC valuation

Is National Research Corporation (NRC) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for National Research Corporation (NRC) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is NRC a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether NRC trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is NRC’s P/E ratio?

You can see NRC’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for NRC?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is NRC a good long-term investment?

Whether NRC fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

NRC

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

Daily snapshot

6.53
MARKETSnap

Trading Metrics:

Open: 19.81   Previous Close: 19.75
Day Low: 19.77   Day High: 21.33
Year Low: 11.01   Year High: 22.79
Price Avg 50: 18.11   Price Avg 200: 16.39
Volume: 42857   Average Volume: 102303

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Is NuScale's NRC Licensing Lead Its Biggest Competitive Advantage?
26-05-2026 09:55
Is NuScale's NRC Licensing Lead Its Biggest Competitive Advantage?
NRC Issues Environmental Assessment with 'Finding of No Significant Impact' for Dow and X-energy's Proposed Advanced Nuclear Project in Texas
18-05-2026 16:05
NRC Issues Environmental Assessment with 'Finding of No Significant Impact' for Dow and X-energy's Proposed Advanced Nuclear Project in Texas
NRC Authorizes FPL's St. Lucie Nuclear Plant to Operate for Another 20 Years
28-04-2026 13:00
NRC Authorizes FPL's St. Lucie Nuclear Plant to Operate for Another 20 Years
Volatus Aerospace Receives NRC-IRAP Funding to Support Condor XL Development
17-03-2026 08:42
Volatus Aerospace Receives NRC-IRAP Funding to Support Condor XL Development
NRC Health Announces Board Authorization of $60 Million Share Repurchase Program
09-03-2026 16:30
NRC Health Announces Board Authorization of $60 Million Share Repurchase Program
NRC Health Provides Business Update
04-03-2026 16:15
NRC Health Provides Business Update

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States

Language

  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read